NCT01626885View on ClinicalTrials.gov

A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Schizophrenia

Interventions

DRUG

MP-214

Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg) of MP-214 for four weeks, then flexible dose (1.5-9 mg) of MP-214

Trial Locations (1)

Unknown

Kurayoshi